BCRX Q2 2025 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$163M+49.4% YoY

Gross Profit

$161M98.3% margin

Operating Income

$30M18.2% margin

Net Income

$5M3.1% margin

EPS (Diluted)

$0.02

QoQ Revenue Growth

+12.2%

Cash Flow

Operating Cash Flow

$41M

Free Cash Flow

$41M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$457M

Total Liabilities

$879M

Stockholders' Equity

-$422M

Cash & Equivalents

$88M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$163M	$109M	+49.4%
Gross Profit	$161M	$108M	+49.2%
Operating Income	$30M	$9M	+240.0%
Net Income	$5M	-$13M	+140.1%

Revenue Segments

Product

$162M99%

Collaborative and Other Research and Development

$923,0001%